Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression
Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.
Expanded Access to TMS Therapy
Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses targeted magnetic pulses to stimulate brain areas linked to mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, researchers have extensively studied TMS, and several countries now include it in treatment guidelines for major depressive disorder, especially when standard therapies fail.
The expanded access initiative responds to growing interest in treatment options that complement existing mental health care. Depression remains a major public health concern, with many individuals experiencing persistent symptoms that affect daily life, work, and overall well-being. Therefore, mental health services increasingly explore safe, evidence-based interventions that clinicians can supervise effectively.
Dr. Shanek Wick, Medical Director at Neuralia TMS, said the expansion demonstrates the clinic’s commitment to making established neuromodulation therapies more widely available. “Transcranial Magnetic Stimulation is a non-invasive treatment supported by a growing body of clinical research for managing depression,” Dr. Wick said. “By broadening access, more patients can be evaluated for suitability within a structured medical framework.”
Comprehensive Neuromodulation Services
Neuralia TMS integrates TMS therapy into a thorough clinical assessment, ensuring treatment plans reflect each patient’s health history and current needs. Clinicians deliver sessions over scheduled appointments, allowing patients to maintain their normal daily routines. Reported side effects are generally mild and temporary, most commonly scalp discomfort or headache during initial sessions.
Beyond depression, Neuralia TMS offers neuromodulation for anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home therapy supervised by clinicians, and pharmacogenetic testing to guide personalized treatment plans. These services complement existing mental health care rather than replace it.
The expansion aligns with trends emphasizing individualized treatment and multidisciplinary care. Clinicians increasingly recognize that effective depression management often combines psychological therapies, medication, and non-invasive interventions. Neuromodulation now forms an important part of this broader continuum.
Advancing Neuromodulation Research
Experts note that non-invasive brain stimulation attracts significant attention as research on brain function and mental health advances. Ongoing studies explore ways to refine protocols and predict outcomes across different patient groups. In this context, clinicians maintain careful oversight and adhere to established standards to ensure responsible implementation.
Dr. Wick said continued evaluation and clinical development remain essential. “Future neuromodulation strategies will involve more precise targeting, improved personalization of treatment protocols, and closer integration with other mental health services,” he said. “Ongoing research and review will guide how we apply these therapies over time.”
Neuralia TMS requires all patients to undergo comprehensive medical assessments before treatment. The clinic follows professional and medical standards, emphasizing informed decision-making and patient safety.
Expanded TMS Access Announcement
The announcement comes amid ongoing discussions about timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS offers additional clinical options for patients and referring practitioners seeking medically supervised alternatives.
For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au.
Company Details
Organization: Neuralia TMS
Contact Person: Dr Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +61862303996
Country: Australia
Release Id: 27012640609